These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 9613981

  • 41. Detection of clonal T-cell receptor gamma gene rearrangements with the use of the polymerase chain reaction in cutaneous lesions of mycosis fungoides and Sézary syndrome.
    Bachelez H, Bioul L, Flageul B, Baccard M, Moulonguet-Michau I, Verola O, Morel P, Dubertret L, Sigaux F.
    Arch Dermatol; 1995 Sep; 131(9):1027-31. PubMed ID: 7661604
    [Abstract] [Full Text] [Related]

  • 42. Expression pattern of chemokine receptors and chemokine release in inflammatory erythroderma and Sézary syndrome.
    Fierro MT, Comessatti A, Quaglino P, Ortoncelli M, Osella Abate S, Ponti R, Novelli M, Bernengo MG.
    Dermatology; 2006 Sep; 213(4):284-92. PubMed ID: 17135733
    [Abstract] [Full Text] [Related]

  • 43. CD4(+)CD7(-) T cells compose the dominant T-cell clone in the peripheral blood of patients with Sézary syndrome.
    Rappl G, Muche JM, Abken H, Sterry W, Tilgen W, Ugurel S, Reinhold U.
    J Am Acad Dermatol; 2001 Mar; 44(3):456-61. PubMed ID: 11209115
    [Abstract] [Full Text] [Related]

  • 44. Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studies.
    Pai RK, Mullins FM, Kim YH, Kong CS.
    Cancer; 2008 Oct 25; 114(5):323-32. PubMed ID: 18798522
    [Abstract] [Full Text] [Related]

  • 45. Extracutaneous transformation into a high-grade lymphoma: a potential pitfall in the management of patients with Sézary syndrome.
    Michaelis S, Kazakov DV, Burg G, Dummer R, Kempf W.
    Int J Dermatol; 2006 Mar 25; 45(3):277-9. PubMed ID: 16533228
    [Abstract] [Full Text] [Related]

  • 46. Skewed expression of activation, differentiation and homing-related antigens in circulating cells from patients with cutaneous T cell lymphoma associated with CD7- T helper lymphocytes expansion.
    Scala E, Russo G, Cadoni S, Narducci MG, Girardelli CR, De Pità O, Puddu P.
    J Invest Dermatol; 1999 Oct 25; 113(4):622-7. PubMed ID: 10504451
    [Abstract] [Full Text] [Related]

  • 47. Abnormal expression of interleukin-23 in mycosis fungoides/Sézary syndrome lesions.
    Doherty SD, Ni X, Doherty CB, Jones D, Zhao X, Owen LB, Duvic M.
    Arch Dermatol Res; 2006 Dec 25; 298(7):353-6. PubMed ID: 17021762
    [Abstract] [Full Text] [Related]

  • 48. A novel mouse model for Sézary syndrome using xenotransplantation of Sézary cells into immunodeficient RAG2(-/-) γc(-/-) mice.
    van der Fits L, Rebel HG, Out-Luiting JJ, Pouw SM, Smit F, Vermeer KG, van Zijl L, Tensen CP, Weijer K, Vermeer MH.
    Exp Dermatol; 2012 Sep 25; 21(9):706-9. PubMed ID: 22897578
    [Abstract] [Full Text] [Related]

  • 49. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas.
    Bosisio FM, Cerroni L.
    Am J Dermatopathol; 2015 Feb 25; 37(2):115-21. PubMed ID: 25406852
    [Abstract] [Full Text] [Related]

  • 50. Simplified flow cytometric assessment in mycosis fungoides and Sézary syndrome.
    Hristov AC, Vonderheid EC, Borowitz MJ.
    Am J Clin Pathol; 2011 Dec 25; 136(6):944-53. PubMed ID: 22095381
    [Abstract] [Full Text] [Related]

  • 51. Sézary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and Targets.
    Saulite I, Hoetzenecker W, Weidinger S, Cozzio A, Guenova E, Wehkamp U.
    Biomed Res Int; 2016 Dec 25; 2016():9717530. PubMed ID: 27294147
    [Abstract] [Full Text] [Related]

  • 52. Serum-soluble herpes virus entry mediator levels reflect disease severity and Th2 environment in cutaneous T-cell lymphoma.
    Miyagaki T, Sugaya M, Suga H, Ohmatsu H, Fujita H, Asano Y, Tada Y, Kadono T, Sato S.
    Acta Derm Venereol; 2013 Jul 06; 93(4):465-7. PubMed ID: 23306973
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Variable CD7 expression on T cells in the leukemic phase of cutaneous T cell lymphoma (Sézary syndrome).
    Vonderheid EC, Bigler RD, Kotecha A, Boselli CM, Lessin SR, Bernengo MG, Polansky M.
    J Invest Dermatol; 2001 Sep 06; 117(3):654-62. PubMed ID: 11564173
    [Abstract] [Full Text] [Related]

  • 55. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C.
    J Am Acad Dermatol; 2014 Feb 06; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [Abstract] [Full Text] [Related]

  • 56. Costimulation of cutaneous T-cell lymphoma cells by interleukin-7 and interleukin-2: potential autocrine or paracrine effectors in the Sézary syndrome.
    Foss FM, Koc Y, Stetler-Stevenson MA, Nguyen DT, O'Brien MC, Turner R, Sausville EA.
    J Clin Oncol; 1994 Feb 06; 12(2):326-35. PubMed ID: 8113839
    [Abstract] [Full Text] [Related]

  • 57. Reflectance confocal microscopy features of mycosis fungoides and Sézary syndrome: correlation with histopathologic and T-cell receptor rearrangement studies.
    Mancebo SE, Cordova M, Myskowski PL, Flores ES, Busam K, Jawed SI, Skripnik A, Rajadhyaksha M, Querfeld C.
    J Cutan Pathol; 2016 Jun 06; 43(6):505-15. PubMed ID: 26969149
    [Abstract] [Full Text] [Related]

  • 58. From single-cell signature to prognostic factors: the case of Sézary syndrome.
    Scala E, Narducci MG, Russo G.
    Expert Rev Clin Immunol; 2012 Nov 06; 8(8):699-701. PubMed ID: 23167680
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Mycosis fungoides and Sézary syndrome.
    Hwang ST, Janik JE, Jaffe ES, Wilson WH.
    Lancet; 2008 Mar 15; 371(9616):945-57. PubMed ID: 18342689
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.